Arlington Partners’s Elevance Health ELV Stock Holding History

Arlington Partners’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-58	Closed	-$27.4K	–	113
2023 Q4	$27.4K	Buy	+58	New	+$26.8K	0.01%	169
2023 Q3	–	Sell	-978	Closed	-$435K	–	472
2023 Q2	$435K	Buy	978 +21	+2%	+$9.69K	0.07%	96
2023 Q1	$440K	Buy	957 +70	+8%	+$33.3K	0.06%	87
2022 Q4	$455K	Hold	887	–	–	0.07%	66
2022 Q3	$403K	Hold	887	–	–	0.16%	66
2022 Q2	$428K	Hold	887	–	–	0.14%	73
2022 Q1	$436K	Hold	887	–	–	0.12%	75
2021 Q4	$411K	Buy	887 +58	+7%	+$24.4K	0.11%	76
2021 Q3	$309K	Buy	+829	New	+$315K	0.09%	82
2020 Q3	–	Sell	-13	Closed	-$3K	–	145
2020 Q2	$3K	Hold	13	–	–	﹤0.01%	147
2020 Q1	$3K	Buy	+13	New	+$3.54K	﹤0.01%	218

Other funds holding ELV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Arlington Partners's ELV Position: Q1 2024 in Review

Arlington Partners sold out of Elevance Health (ELV) in Q1 2024, closing a stake of 58 shares — an estimated $27.4K sold.

Arlington Partners first reported a position in ELV in Q1 2020 and held it in 11 quarters. The position peaked at $455K in Q4 2022. 1,666 funds tracked by Wall St. Rank hold ELV as of Q1 2024.

Arlington Partners reported no remaining Elevance Health position as of Q1 2024 after selling out during the quarter.
Arlington Partners sold 58 Elevance Health shares in Q1 2024, an estimated $27.4K.
Arlington Partners first reported a position in Elevance Health in Q1 2020 and held it in 11 quarters.
Arlington Partners's Elevance Health position peaked at $455K in Q4 2022.
1,666 funds tracked by Wall St. Rank held Elevance Health as of Q1 2024.

Based on Arlington Partners's 13F filing for Q1 2024, filed 16 Apr 2024.